Press Releases

Date	Title
10/3/12	Sarepta Therapeutics Announces Eteplirsen Meets Primary Endpoint of Increased Novel Dystrophin and Achieves Significant Clinical Benefit on 6-Minute Walk Test After 48 Weeks of Treatment in Phase IIb Study in Duchenne Muscular Dystrophy
10/2/12	Sarepta Therapeutics Announces Conference Call and Webcast on Wednesday, October 3, 2012, to Discuss 48-Week Results From the Phase IIb DMD Study
9/18/12	Sarepta Therapeutics' Lead Therapeutic Drugs for Ebola and Marburg Viruses Receive FDA Fast Track Designation
9/13/12	Sarepta Therapeutics to Present Company Overview at the 2012 UBS Global Life Sciences Conference
9/6/12	Market Influences That Drive Equities Forward - Industry Report on Sarepta Therapeutics, Inc. and Boston Scientific Corporation
9/5/12	Sarepta Therapeutics Announces Presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
9/4/12	Sarepta Therapeutics Announces At-the-Market Equity Offering
9/4/12	Sarepta Therapeutics Awarded $3.9 Million Contract by U.S. Government to Evaluate Feasibility of an Alternate Route of Administration of Its Lead Therapeutic Candidate for Treatment of Marburg Virus
8/31/12	Sarepta Therapeutics to Present Company Overview at the 2012 Rodman & Renshaw Annual Global Investment Conference
8/29/12	Sarepta Therapeutics to Present Company Overview at the Stifel Nicolaus 2012 Healthcare Conference

IR Menu